Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate

BACKGROUND: Hereditary angioedema (HAE) due to C1 inhibitor deficiency manifests as recurrent swelling attacks that can be disabling and sometimes fatal. Long‐term prophylaxis with twice‐weekly intravenous injections of plasma‐derived C1‐inhibitor (pdC1‐INH) has been established as an effective trea...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Allergy
Autores principales: Zuraw, B. L., Cicardi, M., Longhurst, H. J., Bernstein, J. A., Li, H. H., Magerl, M., Martinez‐Saguer, I., Rehman, S. M. M., Staubach, P., Feuersenger, H., Parasrampuria, R., Sidhu, J., Edelman, J., Craig, T.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4755045/
https://ncbi.nlm.nih.gov/pubmed/26016741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/all.12658
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares